New research suggests that GLP-1 receptor agonists like semaglutide may reduce muscle strength in mice despite stable muscle size, raising questions for older populations. Policy shifts in the US Centers for Medicare and Medicaid Services (CMS) indicate possible reintroduction of Medicare coverage pilot for GLP-1 obesity drugs, reversing prior exclusions. Additionally, Innovent Biologics' oral GLP-1 agonist entered phase I clinical trials following FDA IND clearance, reflecting industry momentum in this therapeutic class.